Show simple item record

dc.contributor.authorConzade, Romy
dc.contributor.authorGrill, Eva
dc.contributor.authorBischoff-Ferrari, Heike A.
dc.contributor.authorFerrari, Uta
dc.contributor.authorHorsch, Alexander
dc.contributor.authorPeters, Annette
dc.contributor.authorThorand, Barbara
dc.date.accessioned2020-03-26T08:05:23Z
dc.date.available2020-03-26T08:05:23Z
dc.date.issued2019-05-08
dc.description.abstractSummary We report low baseline 25-hydroxyvitamin D (25OHD) levels being associated with unfavorable changes in muscle mass and physical performance over three years, but not with incident sarcopenia. Future prospective studies are needed to assess causality and to address the issue of competing risks such as mortality in older cohorts. Introduction Effects of low serum 25-hydroxyvitamin D (25OHD) on age-related changes in muscle mass and function remain unclear. Our aims were to explore associations of baseline 25OHD levels with prevalent and incident sarcopenia and changes in muscle parameters, and to examine the role of parathyroid hormone (PTH) therein. Methods Cross-sectional (n=975) and prospective analyses (n=702) of older adults aged 65-93 years participating in the KORA-Age study. Sarcopenia was defined using the 2010 European Working Group on Sarcopenia in Older People (EWGSOP) criteria as low muscle mass combined with low grip strength or low physical performance. Associations with baseline 25OHD were examined in multiple regression analyses. Results Low vitamin D status was linked to increased odds of prevalent sarcopenia. Over three years, low baseline 25OHD <25 vs. ≥50 nmol/L were associated with greater loss of muscle mass and increased time for the Timed Up and Go test. The risk for developing incident sarcopenia was not significantly elevated in individuals with low baseline 25OHD but when including death as combined outcome alongside incident sarcopenia, there was a strong positive association in multivariable analysis (OR (95% CI): 3.19 (1.54-6.57) for 25OHD <25 vs. ≥50 nmol/L). There was no evidence for a PTH-mediating effect. Conclusion Low baseline 25OHD levels were associated with unfavorable changes in muscle mass and physical performance, but not with incident sarcopenia. Future randomized trials are needed to assess causality and to address the issue of competing risks such as mortality in older cohorts.en_US
dc.identifier.citationConzade, R.; Grill, E.; Bischoff-Ferrari, H.A; Ferrari, U.; Horsch, A.; König, W., Peters, A.; Thorand, B. (2019) Vitamin D in relation to incident sarcopenia and changes in muscle parameters among older adults: The KORA-Age Study.<i> Calcified Tissue International, 105,</i> (2), 173-182en_US
dc.identifier.cristinIDFRIDAID 1796724
dc.identifier.doi10.1007/s00223-019-00558-5
dc.identifier.issn0171-967X
dc.identifier.issn1432-0827
dc.identifier.urihttps://hdl.handle.net/10037/17855
dc.language.isoengen_US
dc.publisherSpringerNatureen_US
dc.relation.journalCalcified Tissue International
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright Springeren_US
dc.subjectVDP::Medical disciplines: 700::Health sciences: 800en_US
dc.subjectVDP::Medisinske Fag: 700::Helsefag: 800en_US
dc.titleVitamin D in relation to incident sarcopenia and changes in muscle parameters among older adults: The KORA-Age Studyen_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record